Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Table 3 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort (overall survival)

Dependent: Survival (OS/30, status OS)		All, n (%)	HR (univariable)	HR (multivariable)
Gender	Male	90 (61.2)	-	-
	Female	57 (38.8)	0.74 (0.41-1.34, P = 0.316)	0.94 (0.51-1.74, P = 0.848)
Age (year)	≤ 60	75 (51.0)	-	-
	> 60	72 (49.0)	1.25 (0.71-2.19, P = 0.434)	0.98 (0.55-1.74, P = 0.942)
ECOG score	0-1	135 (91.8)	-	-
	2	12 (8.2)	1.03 (0.37-2.87, P = 0.957)	-
Primary tumor location	Right colon	49 (33.3)	-	-
	Left colon and rectum	98 (66.7)	1.00 (0.56-1.78, P = 0.992)	-
No. of metastatic organs	1	88 (59.9)	-	-
	≥ 2	59 (40.1)	1.49 (0.85-2.60, P = 0.164)	-
Liver metastasis	No	64 (43.5)	-	-
	Yes	83 (56.5)	3.55 (1.88-6.69, P < 0.001)	3.48 (1.80-6.72, P < 0.001)
Lung metastasis	No	105 (71.4)	-	-
	Yes	42 (28.6)	0.73 (0.38-1.39, P = 0.335)	-
RAS	Wild type	22 (15.0)	-	-
	Mutation	28 (19.0)	0.92 (0.41-2.07, P = 0.842)	-
	Unknown	97 (66.0)	0.63 (0.31-1.27, P = 0.195)	-
Group	Control group	107 (72.8)	-	-
	Experimental group	40 (27.2)	0.61 (0.28-1.30, P = 0.197)	0.70 (0.32-1.52, P = 0.367)

n = 148, events = 51, Likelihood ratio test = 17.74 on 1 df (P < 0.001). OS: Overall survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group.